Since IL-33 can polarize neutrophils, the key regulatory cells in asthma [30], we found that the eosinophil-activator IL-33 was significantly reduced in the BAL fluid of the 8-day PHF treatment group (p < 0.05) (Figure 2J). Here, IL33 is linked to asthma.